Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Pharmadrug Inc
(CSE:
PHRX
)
0.0200
UNCHANGED
Streaming Delayed Price
Updated: 3:33 PM EDT, Sep 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
0.0200
Bid (Size)
0.0150 (386,000)
Ask (Size)
0.0250 (139,000)
Prev. Close
0.0200
Today's Range
0.0200 - 0.0200
52wk Range
0.0050 - 0.0750
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
PharmaTher’s Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine’s Potential to Bind to Monkeypox (Mpox) Proteins
August 21, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher’s Sairiyo Therapeutics Receives Approval to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine)
August 19, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Performance
YTD
-60.00%
-60.00%
1 Month
+33.33%
+33.33%
3 Month
-20.00%
-20.00%
6 Month
-63.64%
-63.64%
1 Year
+300.00%
+300.00%
More News
Read More
PharmaTher’s Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine
May 15, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
May 01, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia
February 21, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Biotech Veteran David Kideckel Joins the Board of PharmaDrug
August 30, 2021
Via
Newsfile
Topics
Cannabis
Exposures
Cannabis
Product Safety
PharmaDrug Announces Clinical Research Collaboration with The Johns Hopkins University to Evaluate DMT in a Comparative Clinical Study
August 25, 2021
Via
Newsfile
Topics
Cannabis
Exposures
Cannabis
Product Safety
PharmaDrug Announces Appointment of Auditor
August 06, 2021
Via
Newsfile
Topics
Cannabis
Exposures
Cannabis
PharmaDrug Forms Research Collaboration with Terasaki Institute for Novel Ocular Drug Formulation Program to Deliver DMT and Other Tryptamines to Treat Eye Disease
August 05, 2021
Via
Newsfile
Topics
Cannabis
Law Enforcement
Exposures
COVID-19
Cannabis
Legal
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.